First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients

Trial Profile

First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs IVAC-M-uID (Primary) ; IVAC-W-bre1-uID (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms MERIT; TNBC-MERIT
  • Sponsors BioNTech
  • Most Recent Events

    • 10 Oct 2017 Planned number of patients changed from 30 to 42.
    • 09 Sep 2017 Trial design of the study presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
    • 11 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top